施用西洛斯塔可通过修改胆固醇功能和神经炎症来缓解老鼠记忆丧失模型中的学习和记忆障碍
Sakineh Sadat Mortazavi Sani1, Akram Eidi1, Arezoo Rajabian2,3
1Department of Biology, SR.C., Islamic Azad University, Tehran, Iran.
Molecular neurobiology
|November 21, 2025
概括
奇洛斯塔 (Cil) 和多内佩西尔 (DNP) 改善了斯科波拉胺诱导的失忆症的老鼠的记忆和认知功能. 这两种药物都减少了氧化应激和神经炎症,这表明对认知障碍的治疗潜力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 斯科波胺通过破坏胆能系统和氧化平衡来诱导失忆症.
- 固醇 (Cil) 是一种固酶-3抑制剂,在治疗轻度认知障碍方面表现有前途.
研究的目的:
- 为了研究Cil在斯科波胺诱导的记忆丧失的老鼠模型中的神经保护作用和机制.
- 为了比较Cil与多内佩西尔 (DNP) 的疗效,这是一种标准治疗,在缓解认知缺陷方面.
主要方法:
- 在斯科波拉胺诱导的失忆症后,小鼠用Cil或DNP口服治疗了三周.
- 行为测试 (莫里斯水迷宫,被动回避) 评估学习和记忆.
- 对海马组织的神经化学分析测量了氧化应激标志物,乙胆酶 (AChE) 活性和炎症性细胞因子 (TNF-α,IL-1β).
主要成果:
- Cil和DNP都显著改善了空间学习,记忆,并减少了暴露于斯科波胺的老鼠的逃脱延迟和路径长度.
- 用Cil和DNP治疗通过降低脂质过氧化和增加抗氧化标志物 (硫基,SOD活性) 来减轻氧化应激.
- Cil和DNP抑制了皮胺诱导的海马体ACHE活性,TNF-α和IL-1β的增加,同时上调CHRM1mRNA的表达.
结论:
- 奇洛斯塔在老鼠中显示出显著的神经保护作用,对抗斯科波拉胺诱导的认知障碍.
- 通过恢复氧化还原平衡,调节胆固醇活性和减少神经炎症来缓解记忆丧失.
- 这些发现支持Cil对认知障碍的潜在治疗应用.
更多相关视频
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.7K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
12.5K
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
523
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
523
Alzheimer's Disease: Treatment
772
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
772
